Literature DB >> 18997051

Preoperative 123I/99mTc-sestamibi subtraction SPECT and SPECT/CT in primary hyperparathyroidism.

Donald R Neumann1, Nancy A Obuchowski, Frank P Difilippo.   

Abstract

UNLABELLED: The trend toward focused surgical parathyroidectomy requires precise preoperative localization of parathyroid lesions in patients with hyperparathyroidism. The purpose of this study was to directly compare the diagnostic accuracy of (99m)Tc-sestamibi/(123)I subtraction SPECT with SPECT/CT for the localization of abnormal parathyroid glands in patients with primary hyperparathyroidism.
METHODS: A total of 61 consecutive surgical patients with primary hyperparathyroidism underwent both (123)I/(99m)Tc-sestamibi subtraction SPECT and SPECT/CT scans preoperatively, using a hybrid SPECT/CT instrument that combined a dual-detector SPECT camera with a 6-slice multidetector spiral CT scanner. Four hours after being given (123)I-sodium iodide orally, each patient received (99m)Tc-sestamibi intravenously, followed immediately by a simultaneous, dual-isotope SPECT scan of the neck and upper chest. Then, without moving the patient, we performed a non-contrast-enhanced CT scan of the same body region. Normalization and subtraction of the (123)I SPECT images from the (99m)Tc SPECT images were performed. The subtraction SPECT and the coregistered fused SPECT/CT studies were interpreted separately, with images scored on a 5-point scale. Surgical and histopathologic findings were used as the standard of comparison.
RESULTS: Surgery was successful in 57 patients (solitary parathyroid adenoma in 48 patients, double parathyroid adenomas in 6 patients, and 10 hyperplastic parathyroid glands in 3 patients). The sensitivities of SPECT (50/70 = 71%) and SPECT/CT (49/70 = 70%) were similar (P = 0.779). The specificity of SPECT/CT (26/27 = 96%) was significantly greater than that of SPECT (13/27 = 48%; P = 0.006). The receiver-operating-characteristic area under the curve of SPECT/CT (0.833) was significantly greater than that of SPECT (0.632; P < 0.001).
CONCLUSION: SPECT/CT is significantly more specific than dual-isotope subtraction SPECT for the preoperative identification of parathyroid lesions in patients with primary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18997051     DOI: 10.2967/jnumed.108.054858

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  17 in total

Review 1.  Multiplexed imaging in cancer diagnosis: applications and future advances.

Authors:  Hisataka Kobayashi; Michelle R Longmire; Mikako Ogawa; Peter L Choyke; Satomi Kawamoto
Journal:  Lancet Oncol       Date:  2010-03-24       Impact factor: 41.316

2.  Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography.

Authors:  Ka-Kit Wong; Arpit Gandhi; Benjamin L Viglianti; Lorraine M Fig; Domenico Rubello; Milton D Gross
Journal:  World J Radiol       Date:  2016-06-28

Review 3.  Imaging for primary hyperparathyroidism--an evidence-based analysis.

Authors:  Radu Mihai; Dietmar Simon; Per Hellman
Journal:  Langenbecks Arch Surg       Date:  2009-07-10       Impact factor: 3.445

Review 4.  SPECT/CT: an update on technological developments and clinical applications.

Authors:  Michael Ljungberg; P Hendrik Pretorius
Journal:  Br J Radiol       Date:  2017-01-16       Impact factor: 3.039

5.  18F-Fluorocholine PET/CT as a second line nuclear imaging technique before surgery for primary hyperparathyroidism.

Authors:  Alessio Imperiale; David Taïeb; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04       Impact factor: 9.236

6.  Solitary Parathyroid Adenoma Localization in Technetium Tc99m Sestamibi SPECT and Multiphase Multidetector 4D CT.

Authors:  T H Vu; D Schellingerhout; N Guha-Thakurta; J Sun; W Wei; S C Kappadth; N Perrier; E E Kim; E Rohren; H H Chuang; F C Wong
Journal:  AJNR Am J Neuroradiol       Date:  2018-12-06       Impact factor: 3.825

7.  Comparison of hyperparathyroidism types and utility of dual radiopharmaceutical acquisition with Tc99m sestamibi and 123I for localization of rapid washout parathyroid adenomas.

Authors:  Y S Kushchayeva; S H Tella; S V Kushchayev; D Van Nostrand; K Kulkarni
Journal:  Osteoporos Int       Date:  2019-01-31       Impact factor: 4.507

8.  A Multimodal Imaging Protocol, (123)I/(99)Tc-Sestamibi, SPECT, and SPECT/CT, in Primary Hyperparathyroidism Adds Limited Benefit for Preoperative Localization.

Authors:  Grace S Lee; Travis J McKenzie; Brian P Mullan; David R Farley; Geoffrey B Thompson; Melanie L Richards
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

9.  Primary hyperparathyroidism: imaging to pathology.

Authors:  Sara Piciucchi; Domenico Barone; Giampaolo Gavelli; Alessandra Dubini; Devil Oboldi; Federica Matteuci
Journal:  J Clin Imaging Sci       Date:  2012-10-06

10.  2009 EANM parathyroid guidelines.

Authors:  Elif Hindié; Omer Ugur; David Fuster; Michael O'Doherty; Gaia Grassetto; Pablo Ureña; Andrew Kettle; Seza A Gulec; Francesca Pons; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-07       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.